Short answer first, then the reasoning. The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.
Alcohol simply stopped appealing, which I did not expect and which has been more socially complicated than the weight loss.
So the question, as narrowly as I can put it: whether the change in tolerance is the smaller stomach, the smaller body, or something central, and whether it settles.
I would rather have one careful answer than five confident ones.
BenResearch_OR said:The liver data is among the strongest non-weight findings in the class.
Agreed, and ALT falling is not the same as fibrosis improving. Enzymes are a crude proxy; FIB-4 or elastography is what tells you about the thing that matters.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsRickReta_CO said:Alcohol simply stopped appealing, which I did not expect and which has been more socially complicated than the weight loss.
Can confirm. Same sequence, different timescale.
Adding the clinical framing, because it changes how the question reads. Worth answering the question that was asked rather than the one behind it. The narrow version usually has an answer; the broad version usually does not, and answering the broad one is how a thread stops being useful.